
Biogen hopes that Plegridy will provide an option for patients seeking a less frequent dosing schedule. Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week. When given once every four weeks, Plegridy
was also shown to be effective and met the main goals of the trial, but patients who received the drug once every two weeks responded better..
CLICK FOR FULL STORY
Labels: Avonex